Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer
- Dr. Gericke brings extensive experience in the research and development of radioligand therapies
- Appointment coincides with launch of Ariceum International AG in Basel, Switzerland
Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Germo Gericke, M.D., as Chief Medical Officer.
